Side effect reduction of encapsulated hydrocortisone crystals by insulin/alginate shells.
Insulin/alginate (ALG) microcapsules for controllable release and side effect reduction of a glucocorticoid have been fabricated via the layer-by-layer (LbL) assembly technique. Insulin and ALG are deposited alternately onto hydrocortisone (HC) crystals to form a core-shell structure. This insulin/ALG microcapsule can prolong the release of HC under physical conditions and control the HC release rate by adjusting the number of insulin/ALG bilayers adsorbed onto HC crystals. The release of insulin from the capsule wall exhibits a little lag, compared with that of the HC. It is a great advantage for this system because hyperglycemia caused by HC usually arises a few hours after its administration, which could be inhibited by the delayed release of insulin from the shell of the microcapsule. This synergy effect might enable a new way of using one carrier to deliver two kinds of drugs and reduce their side effects at the same time.
Beijing National Laboratory for Molecular Sciences (BNLMS), Key Laboratory of Colloid and Interface Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, PR China.
Jie
J
Zhao
Yue
Y
Cui
Anhe
A
Wang
Jinbo
J
Fei
Yang
Y
Yang
Junbai
J
Li
D000464:Alginates / Q000737:chemistry*; D000818:Animals; D002214:Capsules / Q000737:chemistry*; D002417:Cattle; D003460:Crystallization; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D006854:Hydrocortisone / Q000737:chemistry*; D007328:Insulin / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning
D000464:Alginates; D002214:Capsules; D006603:Hexuronic Acids; D007328:Insulin; D020723:Glucuronic Acid; D006854:Hydrocortisone